Nanogroup SA
NanoGroup S.A. operates as a biotechnology company in Poland. The company develops and licenses early-stage pre-clinical and IND solutions to international biotech and pharma companies. It also manages a portfolio of companies that manages projects for the need of modern medicine in the field of oncology and transplantology. The company was incorporated in 2016 and is based in Warsaw, Poland.
Nanogroup SA (NNG) - Net Assets
Latest net assets as of June 2025: zł11.37 Million PLN
Based on the latest financial reports, Nanogroup SA (NNG) has net assets worth zł11.37 Million PLN as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (zł16.63 Million) and total liabilities (zł5.26 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | zł11.37 Million |
| % of Total Assets | 68.35% |
| Annual Growth Rate | N/A |
| 5-Year Change | -15.13% |
| 10-Year Change | 201.78% |
| Growth Volatility | 81.55 |
Nanogroup SA - Net Assets Trend (2014–2024)
This chart illustrates how Nanogroup SA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Nanogroup SA (2014–2024)
The table below shows the annual net assets of Nanogroup SA from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | zł15.93 Million | +208.72% |
| 2023-12-31 | zł5.16 Million | -33.71% |
| 2022-12-31 | zł7.78 Million | -6.97% |
| 2021-12-31 | zł8.37 Million | -55.42% |
| 2020-12-31 | zł18.77 Million | +41.01% |
| 2019-12-31 | zł13.31 Million | -14.27% |
| 2018-12-31 | zł15.52 Million | +9.58% |
| 2017-12-31 | zł14.17 Million | +11.13% |
| 2016-12-31 | zł12.75 Million | +141.55% |
| 2015-12-31 | zł5.28 Million | +2188.52% |
| 2014-12-31 | zł-252.70K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nanogroup SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4211808140.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | zł32.16 Million | 211.58% |
| Other Comprehensive Income | zł-12.21 Million | -80.33% |
| Other Components | zł38.63 Million | 254.15% |
| Total Equity | zł15.20 Million | 100.00% |
Nanogroup SA Competitors by Market Cap
The table below lists competitors of Nanogroup SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Avenira Limited
PINK:MMMKF
|
$12.30 Million |
|
Qingdao Hengshun Zhongsheng
SHE:300208
|
$12.31 Million |
|
Mlk Foods Public Company Ltd
WAR:MLK
|
$12.31 Million |
|
Eastern Platinum Limited
PINK:ELRFF
|
$12.31 Million |
|
Gielda Praw Majatkowych Vindexus S.A.
WAR:VIN
|
$12.30 Million |
|
Higher Way Electronic Co Ltd
TWO:3268
|
$12.30 Million |
|
Malayan United Industries Bhd
KLSE:3891
|
$12.30 Million |
|
Genie Networks Limited
TWO:8298
|
$12.29 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nanogroup SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,476,635 to 15,199,052, a change of 10,722,417 (239.5%).
- Net loss of 5,167,663 reduced equity.
- New share issuances of 15,801,252 increased equity.
- Other comprehensive income increased equity by 188,828.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | zł-5.17 Million | -34.0% |
| Share Issuances | zł15.80 Million | +103.96% |
| Other Comprehensive Income | zł188.83K | +1.24% |
| Other Changes | zł-100.00K | -0.66% |
| Total Change | zł- | 239.52% |
Book Value vs Market Value Analysis
This analysis compares Nanogroup SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.22x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 5.69x to 5.22x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | zł0.44 | zł2.51 | x |
| 2016-12-31 | zł0.95 | zł2.51 | x |
| 2017-12-31 | zł0.98 | zł2.51 | x |
| 2018-12-31 | zł1.09 | zł2.51 | x |
| 2019-12-31 | zł0.88 | zł2.51 | x |
| 2020-12-31 | zł1.05 | zł2.51 | x |
| 2021-12-31 | zł0.46 | zł2.51 | x |
| 2022-12-31 | zł0.42 | zł2.51 | x |
| 2023-12-31 | zł0.22 | zł2.51 | x |
| 2024-12-31 | zł0.48 | zł2.51 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nanogroup SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -34.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -246079.19%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.31x
- Recent ROE (-34.00%) is above the historical average (-44.61%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -13.57% | -9674.13% | 0.00x | 1.10x | zł-1.24 Million |
| 2016 | -6.92% | 0.00% | 0.00x | 1.71x | zł-1.92 Million |
| 2017 | -15.74% | -4935.10% | 0.00x | 1.77x | zł-3.29 Million |
| 2018 | -16.49% | -2125.87% | 0.00x | 1.90x | zł-3.77 Million |
| 2019 | -12.54% | -437.04% | 0.01x | 2.15x | zł-2.76 Million |
| 2020 | -29.40% | -754.79% | 0.02x | 1.70x | zł-6.95 Million |
| 2021 | -129.37% | -2031.60% | 0.02x | 2.63x | zł-10.78 Million |
| 2022 | -11.84% | -600.93% | 0.01x | 2.71x | zł-1.55 Million |
| 2023 | -176.24% | -390778.60% | 0.00x | 1.93x | zł-8.34 Million |
| 2024 | -34.00% | -246079.19% | 0.00x | 1.31x | zł-6.69 Million |
Industry Comparison
This section compares Nanogroup SA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $94,285,466
- Average return on equity (ROE) among peers: -40.48%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nanogroup SA (NNG) | zł11.37 Million | -13.57% | 0.46x | $12.30 Million |
| Bioceltix S.A. (BCX) | $1.91 Million | -83.78% | 0.69x | $71.31 Million |
| Bioton S.A. (BIO) | $619.64 Million | 5.47% | 0.40x | $42.39 Million |
| Captor Therapeutics S.A. (CTX) | $124.20 Million | -26.23% | 0.16x | $69.93 Million |
| Mabion S.A. (MAB) | $-54.16 Million | 0.00% | 0.00x | $31.56 Million |
| Molecure S.A. (MOC) | $126.45 Million | -10.71% | 0.09x | $21.11 Million |
| Pharmena S.A. (PHR) | $8.98 Million | -45.66% | 0.29x | $2.62 Million |
| PolTREG S.A. (PTG) | $12.83 Million | -6.84% | 0.27x | $16.72 Million |
| Pure Biologics Spólka Akcyjna (PUR) | $7.21 Million | -65.22% | 2.02x | $2.90 Million |
| Ryvu Therapeutics SA (RVU) | $1.50 Million | -131.36% | 5.84x | $100.54 Million |